Genzyme - Articles and news items

Phase I/II data for neoGAA in Pompe disease presented

Industry news / 4 March 2016 / Victoria White

Sanofi Genzyme says the safety and efficacy data from the NEO1 study support further development of neoGAA…

Lemtrada treatment effects maintained over five years in RRMS

Industry news / 8 October 2015 / Victoria White

Lemtrada targets CD52, a protein abundant on T and B cells. Circulating T and B cells are thought to be responsible for the damaging inflammatory process in MS…

New data suggests Aubagio slows brain atrophy in RMS

Industry news / 7 October 2015 / Victoria White

MRI data from Genzyme’s Phase III TEMSO study demonstrate that Aubagio significantly slowed brain atrophy in people with relapsing multiple sclerosis (RMS)…

Genzyme opts into Alnylam’s ALN-AT3 haemophilia programme

Industry news / 1 October 2015 / Victoria White

Genzyme has elected to opt into the programme for development and potential future commercialisation of ALN-AT3 in territories outside of North America and Western Europe…

Genzyme initiates Phase 1/2 clinical trial to evaluate olipudase alfa in paediatric patients

Industry news / 16 June 2015 / Victoria White

The first paediatric patient has begun treatment in Genzyme’s Phase 1/2 clinical trial focused on evaluating the investigational therapy olipudase alfa…

FDA grants Breakthrough Therapy designation to Genzyme’s olipudase alfa

Industry news / 4 June 2015 / Victoria White

The FDA has granted Breakthrough Therapy designation to Genzyme’s olipudase alfa for the treatment of Niemann-Pick disease type B…

FDA grants fast track designation to Genzyme’s investigational substrate reduction therapy for the treatment of Fabry disease

Industry news / 29 April 2015 / Victoria White

The FDA has granted Fast Track designation for the development of Genzyme’s GZ/SAR402671, an investigational substrate reduction therapy for Fabry disease…

Genzyme logo

Genzyme’s Lemtrada resubmission accepted for review by FDA

Industry news / 30 May 2014 / Sanofi

Sanofi and its subsidiary Genzyme announced that the U.S. Food and Drug Administration has accepted for review the company’s resubmission of its supplemental Biologics License Application (sBLA) seeking approval of Lemtrada…


Genzyme and Alnylam expand collaboration on rare genetic diseases

Industry news / 13 January 2014 / Sanofi

Genzyme will have significant rights to Alnylam’s portfolio of clinical and pre-clinical stage drug candidates…


Genzyme’s multiple sclerosis franchise featured at ECTRIMS

Industry news / 27 September 2013 / Genzyme

18 platform and poster presentations provide deeper insight into the Clinical Development Programs for Aubagio® and Lemtrada™…


European Commission approves Genzyme’s multiple sclerosis treatment Lemtrada™ (alemtuzumab)

Industry news, News / 17 September 2013 / Genzyme

Follows recent European Commission approval of multiple sclerosis treatment Aubagio® (teriflunomide)…

Genzyme logo

European Commission approves Genzyme’s once-daily, oral multiple sclerosis treatment Aubagio® (teriflunomide)

Industry news, News / 30 August 2013 / Sanofi

Sanofi and its subsidiary Genzyme announced that the European Commission has granted marketing authorization for Aubagio® (teriflunomide)…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...